Eli Lilly Sues Par Pharma To Block Generic Effient

Law360, New York (January 29, 2014, 6:30 PM EST) -- Eli Lilly and Co. Ltd. and other drugmakers sued Par Pharmaceutical Cos. Inc. on Friday in New Jersey federal court, alleging the company’s proposed generic version of Effient, used to manage cardiovascular events in patients with acute coronary syndrome, infringes their patents.

Lilly, Ube Industries Ltd., Daiichi Sankyo Co. Ltd. and its subsidiary claim the abbreviated new drug application that Par filed with the U.S. Food and Drug Administration seeking approval to manufacture and market a generic version of Effient infringes two of Daiichi Sankyo's and...
To view the full article, register now.